Trial Profile

NeoOPTIMIZE: An Open-Label, Phase II Trial to Assess the Efficacy of Adaptive Switching of FOLFIRINOX or Gemcitabine/Nab-Paclitaxel as a Neoadjuvant Strategy for Patients With Resectable and Borderline Resectable/Locally Advanced Unresectable Pancreatic Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; Losartan (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Capecitabine
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Therapeutic Use
Acronyms NeoOPTIMIZE

03 Jan 2025 Status changed from recruiting to active, no longer recruiting.
11 Apr 2024 Planned primary completion date changed from 15 Apr 2024 to 15 Apr 2025.
12 Nov 2023 Treatments section is updated to add the procedures of Bio-specimen collection and diagnostic imaging.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com